1,393 results on '"Kung, Andrew L."'
Search Results
102. Supplementary Figure Legend from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
103. Supplementary Data from Translational Strategies for Repotrectinib in Neuroblastoma
104. Supplemental Figure 2 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
105. Supplementary Table 3 from Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion–Driven Cancer
106. Supplementary Methods, Figure Legends from Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer
107. Supplementary Fig. S1 from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
108. Supplementary Figure 4 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
109. Data from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
110. Supplementary Figure 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
111. Data from Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia
112. Supplementary Figure from Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia
113. Supplementary Figure Legends from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
114. Supplementary Tables S1-S3 and Supplementary Figures S1-S6 from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
115. Supplementary Table 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
116. Supplementary Figure 1 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
117. Supplementary Figure Legends from Targeted Imaging of Ewing Sarcoma in Preclinical Models Using a 64Cu-Labeled Anti-CD99 Antibody
118. Supplementary Figure 6 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
119. Supplementary Figure 4 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
120. Supplementary Figure Legends from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
121. Supplementary Figure 5F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
122. Supplementary Methods from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
123. Supplementary Figure 5A-5E from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
124. Supplementary Figure 8 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
125. Data from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
126. Supplementary Figure 2 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
127. Supplementary Figures from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
128. Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
129. Supplementary Table S1 from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
130. Supplementary Methods from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
131. Supplementary Figure 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
132. Supplementary Figures 1 - 3 from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
133. Supplementary Figures from Targeted Imaging of Ewing Sarcoma in Preclinical Models Using a 64Cu-Labeled Anti-CD99 Antibody
134. Supplementary figure 5 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
135. Supplementary Figure 3 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
136. Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
137. Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
138. Supplementary Data from Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia
139. Supplementary Table 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
140. Supplementary Figure Legends from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
141. Supplementary Patient Data from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
142. Data from Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming
143. Supplementary Methods and Legends from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
144. Supplementary Figure 1 from Widespread CXCR4 Activation in Astrocytomas Revealed by Phospho-CXCR4-Specific Antibodies
145. Supplementary Tables 1 - 3 from High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma
146. Supplementary Figures 1 - 5 from High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma
147. Supplementary Figures 1-2 from Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming
148. Data from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
149. Supplementary Figures 1-4, Tables 1-4 from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
150. Data from High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.